Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- All-Case Surveillance Lifted for Humira for Crohn’s Disease: Abbott Japan/Eisai
October 31, 2012
- Asahi Kasei Pharma Launches Global PIII Trial for Recomodulin
October 31, 2012
- Astellas Launches Quadruple Vaccine Quattrovac on October 31
October 31, 2012
- Takeda Files NDA in Japan for Cetilistat for Treatment of Obesity
October 31, 2012
- Mitsubishi Tanabe Reports Growth in 1st-Half Sales with Boost from Remicade, Telavic
October 31, 2012
- Kyowa Hakko Bio to Set Up New Plant in Thailand in Response to Rising Demand for Amino Acids
October 30, 2012
- Equity Participation in ViiV Hoped to Cover Patent Loss of Crestor: Shionogi Pres. Teshirogi
October 30, 2012
- Major Japanese Drug Makers Strengthen Vaccine Business, Eyeing Global Operations
October 30, 2012
- Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
- DSP, Takeda Submit Application for Antipsychotic Lurasidone in Europe
October 30, 2012
- Nihon Chouzai to Make Choseido its Subsidiary to Strengthen Generic Products Supply Capacity
October 30, 2012
- Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
- Kyowa Kirin: Pharmaceutical Sales Up 8.4%, but Domestic Sales Down in January to September Period
October 29, 2012
- Nippon Chemiphar Revises 1st Half Business Forecast Upward, Full Year Forecast Unchanged
October 29, 2012
- MTPC to Launch Quadruple Vaccine TETRABIK on October 31 with 50 Vaccine Specialized MRs
October 29, 2012
- Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
- Everlth President Hasegawa Sends Out Information to World on Activities of Pharmaceutical Wholesalers at Time of Great East Japan Earthquake
October 26, 2012
- Takeda Starts Detailing Activities through M3’s “Tenohira MR-kun” on iPads
October 26, 2012
- AnGes MG Inks Definitive Deal to Grant Exclusive US Marketing Rights for Collategene to MTPC
October 25, 2012
- Kyowa Kirin to Construct Biopharmaceutical API Manufacturing Facility
October 25, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…